EPC-005

N/A

Report date: 2025/01/26 17:54:52

Base Information

Drug NameEPC-005

Drug Alias NameEPC-005

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionAnti-CD123

TargetsInterleukin-3 receptor subunit alpha

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesElpis BioPharmaceuticals Corp

China Registration ClassN/A

Develop Information

Active CompaniesElpis BioPharmaceuticals Corp

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A